Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer

Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer

US Patent 11951190 · Granted Apr 9, 2024

Estimated economic value: $27,521,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Double-labeled probe for molecular imaging and use thereof2024
Double-labeled probe for molecular imaging and use thereof2024
18F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use2024
18F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use2024
18F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use2024
18F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use2024
Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for th2024
Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for th2024
Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for th2024
Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for th2024
Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for th2024
Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for th2024